More tools:Markets·Screener·Research·Chat

REGENXBIO Inc. (RGNX) Financial Statements

REGENXBIO Inc.
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG007Z9V5C7
XNAS · usd
8.76▼ 0.18 (-2.01%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close8.94
Day's Range8.60 – 8.95
52-Week Range5.46 – 16.19
Volume973.6K
Avg Volume1.2M
Share Statistics
Shares Outstanding
Employees371
ExchangeXNAS
Listed2015-09-17
Share count as of July 31, 2026
Loading Income Statement…
Key questions about REGENXBIO Inc. (RGNX)
What is REGENXBIO Inc.'s Market Cap?
REGENXBIO Inc.'s Market Cap is $578.3M, based on as-reported figures from SEC (XBRL) filings.
What is REGENXBIO Inc.'s Enterprise Value?
REGENXBIO Inc.'s Enterprise Value is $472.8M, based on as-reported figures from SEC (XBRL) filings.
What is REGENXBIO Inc.'s Price / Sales?
REGENXBIO Inc.'s Price / Sales is 3.3×, based on as-reported figures from SEC (XBRL) filings.
What is REGENXBIO Inc.'s EV / Revenue?
REGENXBIO Inc.'s EV / Revenue is 2.7×, based on as-reported figures from SEC (XBRL) filings.
What is REGENXBIO Inc.'s EV / EBITDA?
REGENXBIO Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is REGENXBIO Inc.'s Revenue (TTM)?
REGENXBIO Inc.'s Revenue (TTM) is $174.5M, based on as-reported figures from SEC (XBRL) filings.
What is REGENXBIO Inc.'s Net Income (TTM)?
REGENXBIO Inc.'s Net Income (TTM) is -$196.4M, based on as-reported figures from SEC (XBRL) filings.
What is REGENXBIO Inc.'s EBITDA?
REGENXBIO Inc.'s EBITDA is -$148.8M, based on as-reported figures from SEC (XBRL) filings.
What is REGENXBIO Inc.'s Diluted EPS (TTM)?
REGENXBIO Inc.'s Diluted EPS (TTM) is -2.98, based on as-reported figures from SEC (XBRL) filings.
What is REGENXBIO Inc.'s EBITDA Margin?
REGENXBIO Inc.'s EBITDA Margin is -85.3%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
Revenues
YoY growth+405.7%-92.8%+43.0%+22.9%
Operating Expenses
Cost of license and royalty revenues
Research and development
General and administrative
Other operating expenses
Total operating expenses
% of revenue72.9%1404.0%290.0%276.3%
Income (loss) from operations
% of revenue27.1%-1304.0%-190.0%-176.3%
Other Income (Expense)
Interest income from licensing
Investment income
Interest expense
Total other income (expense)
Net income (loss)
% of revenue21.0%-1408.6%-221.3%-208.3%
Basic—
Diluted—